AUAUniversity

Take Home Messages: Infertility/Andrology

Sarah Vij, MD

Cleveland Clinic Foundation

Take Home Messages: Sexual Dysfunction

Faysal Yafi, MD

University of California Irvine

Take Home Messages in Endourology/Stones and Transplantation

Endourology/Stones:

Nishant Patel, MD

UCLA Health System

Transplantation:

Nicholas Cowan, MD

Urologist, Transplant surgeon

Virginia Mason Medical Center

Take Home Messages: Basic Science (Benign)

Travis Jerde, PHD

Associate Professor of Pharmacology and Toxicology

Indiana University School of Medicine

Take Home Messages: Basic Science (Malignant)

Donald Vander Griend, PhD

Associate Professor

The University of Illinois at Chicago

Moderator(s)

A. Lenore Ackerman, MD

Cedars-Sinai Medical Center

Panelist(s)

Toby Chai, MD

Professor

Yale University School of Medicine

Duane Hickling, MD

The Ottawa Hospital, The Ottawa Research Institute

Kimberly Kenton, MD

MD, MS

Northwestern

Ann Stapleton, MD

Professor of Medicine

University of Washington

Jennifer Anger, MD, MPH

Cedars-Sinai Medical Center

Support provided by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech and Merck

CME Available: https://auau.auanet.org/node/25249

This course will review the most recent AUA practice guidelines for non-muscle-invasive bladder cancer and detail strategies to manage common clinical predicaments involved in the management of these tumors. Specifically we will review: the AUA guidelines; risk stratification and use of cystectomy; selection of the optimal intravesical agent at the right schedule; and treatment of toxicity from intravesical therapy. Practical solutions will be presented that can be readily integrated into the office setting. Emphasis is placed on the evaluation of real clinical cases with open audience participation.

This educational series is supported by independent educational grants from:

AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme

Episode 3: Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents and Radionuclide Therapy and Bone Health

Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents

David F. Jarrard, MD

Radionuclide Therapy and Bone Health

Steve Boorjian, MD

CME Available: auau.auanet.org/node/25405

The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.

To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

CME Available: https://auau.auanet.org/content/novel-agents-concepts-management-hormone-na%C3%AFve-castrate-resistant-prostate-cancer-webcast-0

This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.

Learning Objectives:

Diagnose both non-metastatic and metastatic castrate resistant prostate cancer (nmCRPC, mCRPC) and have a working knowledge of treatments and the proper order for administration.

Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy.

Analyze the mechanism of action and risks/benefits of using systemic agents in the treatment of nm/mCRPC.

Describe the bone-targeted, radiopharmaceutical agent and its sequencing.

Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC.

This educational series is supported by independent educational grants from:

AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme

Episode 2: Setting Up and Managing Advanced Prostate Cancer in the Community Setting: Unique Challenges and the Role of Chemotherapy, Treatment Sequencing and Future Approaches

CME Available: https://auau.auanet.org/node/25404

The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.

To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

CME Available: https://auau.auanet.org/node/24579

Instructional Course Director(s)

Danil Makarov, MD photo

Danil Makarov, MD

New York University School of Medicine

Instructional Course Faculty(s)

Michael Barry, MD

Harvard Medical School

Angela Fagerlin, MD

Chair, Department of Population Health Sciences

Shared Decision Making was recently accepted as the standard of care when counseling patients considering PSA screening by the US Preventative Services Taskforce. Shared Decision Making is also embedded into numerous recently published AUA guidelines (including the localized prostate cancer guideline). In spite of these clear recommendations, Shared Decision Making is not frequently used in clinical practice.

We propose a course that would teach the essentials of Shared Decision Making (SDM) to practicing urologists who help patients decide about prostate cancer screening and treatment. The course will go over the latest research documenting the benefits and drawbacks of Shared Decision Making when counseling patients considering PSA screening as well as treatment approaches for incident localized prostate cancer. It will also teach the participants how to practice SDM with their patients and will engage them in group-based role play. At the end of the session, participants will understand how to apply SDM in their practice.

Learning Objectives:

Explain Shared Decision Making.

Discuss the impact of shared decision making on patients and on patient-clinician communication.

Describe at least one implementation strategy for using shared decision making in clinical practice.

Explain Shared Decision Making techniques in a role playing exercise with other attendees.

Apply the knowledge they have gained through role play into their routine practice counseling patients.

This educational series is supported by independent educational grants from:

AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme

Episode 1: Genetic Testing in Advanced Prostate Cancer and the Identification of High Risk Disease and Initial Management of Biochemical Recurrence

CME Available: https://auau.auanet.org/node/25403

The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.

To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.